Company Profile

Atterx Biotherapeutics (AKA: ConjuGon Inc)
Profile last edited on: 4/2/2019      CAGE: 39GT2      UEI: JVPUJS93NLX6

Business Identifier: Therapeutics for antibiotic-resistant bacterial infections
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

505 South Rosa Road Suite 117
Madison, WI 53719
   (608) 441-2794
Location: Single
Congr. District: 02
County: Dane

Public Profile

Renamed Atterx Biotherapeutics in late 2014/early 2015, , ConjuGon (now Atterx) has been working on development of fundamentally new therapeutics to combat the growing epidemic of antibioticresistant bacterial infections. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. The firm's core technology is a new way to kill unwanted and even multi-drug resistant bacteria. In the product piepline are 2 drugs, one to combat catheter-associated urinary tract infections (CAUTIs), and another to treat resistant infections of large wounds caused by Gram negative bacteria

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 2 Army $846,085
Project Title: Fundamentally New Therapeutic for the Treatment of Acinetobacter Baumannii Wound Infections
2004 2 NSF $598,560
Project Title: A New Biotherapeutic Approach to Combating Unwanted Bacteria

Key People / Management

  Gary Greenwood -- Chairman of the Board & President

  Sal Braico

  Richard Burgess -- Founder

  Marcin Filutowicz -- Founder

  Ron Kuehn -- Vice President

  Steven R Watt -- Chief Operating Officer

Company News

There are no news available.